[TimAlerts] OPKO dying on news of clinical trial failures

[TimAlerts] OPKO Health (NASDAQ: OPK) reported Q2 EPS of $0.02, versus ($0.09) reported last year. Revenue for the quarter came in at $357.1 million, versus $42.4 million reported last year.

[TimAlerts] OPKO this could run OPKO Announces Submission of Rayaldee(TM) New Drug Application to U.S. Food and Drug Administration